32 results on '"Ray-Coquard, Isabelle"'
Search Results
2. ENDOLUNG trial. A phase 1/2 study of the Akt/mTOR inhibitor and autophagy inducer Ibrilatazar (ABTL0812) in combination with paclitaxel/carboplatin in patients with advanced/recurrent endometrial cancer
- Author
-
Leary, Alexandra, Estévez-García, Purificación, Sabatier, Renaud, Ray-Coquard, Isabelle, Romeo, Margarita, Barretina-Ginesta, Pilar, Gil-Martin, Marta, Garralda, Elena, Bosch-Barrera, Joaquim, Morán, Teresa, Martin-Martorell, Paloma, Nadal, Ernest, Gascón, Pere, Rodon, Jordi, Lizcano, Jose M, Muñoz-Guardiola, Pau, Fierro-Durán, Gemma, Pedrós-Gámez, Oriol, Pérez-Montoyo, Héctor, Yeste-Velasco, Marc, Cortal, Marc, Pérez-Campos, Antonio, Alfon, Jose, Domenech, Carles, Pérez-Fidalgo, Alejandro, and Oaknin, Ana
- Published
- 2024
- Full Text
- View/download PDF
3. Clinical, pathological, and comprehensive molecular analysis of the uterine clear cell carcinoma: a retrospective national study from TMRG and GINECO network
- Author
-
Nigon, Elsa, Lefeuvre-Plesse, Claudia, Martinez, Alejandra, Chauleur, Céline, Lortholary, Alain, Favier, Laure, Bats, Anne-Sophie, Guille, Arnaud, AdélaÏde, José, Finetti, Pascal, de Casteljac, Victoire, Provansal, Magali, Mamessier, Emilie, Bertucci, François, Ray-Coquard, Isabelle, and Sabatier, Renaud
- Published
- 2023
- Full Text
- View/download PDF
4. What underlies the observed hospital volume-outcome relationship?
- Author
-
Huguet, Marius, Joutard, Xavier, Ray-Coquard, Isabelle, and Perrier, Lionel
- Published
- 2022
- Full Text
- View/download PDF
5. Determinants of the access to remote specialised services provided by national sarcoma reference centres
- Author
-
Fayet, Yohan, Tétreau, Raphaël, Honoré, Charles, Le Nail, Louis-Romée, Dalban, Cécile, Gouin, François, Causeret, Sylvain, Piperno-Neumann, Sophie, Mathoulin-Pelissier, Simone, Karanian, Marie, Italiano, Antoine, Chaigneau, Loïc, Gantzer, Justine, Bertucci, François, Ropars, Mickael, Saada-Bouzid, Esma, Cordoba, Abel, Ruzic, Jean-Christophe, Varatharajah, Sharmini, Ducimetière, Françoise, Chabaud, Sylvie, Dubray-Longeras, Pascale, Fiorenza, Fabrice, De Percin, Sixtine, Lebbé, Céleste, Soibinet, Pauline, Michelin, Paul, Rios, Maria, Farsi, Fadila, Penel, Nicolas, Bompas, Emmanuelle, Duffaud, Florence, Chevreau, Christine, Le Cesne, Axel, Blay, Jean-Yves, Le Loarer, François, and Ray-Coquard, Isabelle
- Published
- 2021
- Full Text
- View/download PDF
6. Correction to: Beyond the map: evidencing the spatial dimension of health inequalities
- Author
-
Fayet, Yohan, Praud, Delphine, Fervers, Béatrice, Ray-Coquard, Isabelle, Blay, Jean-Yves, Ducimetiere, Françoise, Fagherazzi, Guy, and Faure, Elodie
- Published
- 2021
- Full Text
- View/download PDF
7. “Chronic fatigue, quality of life and long-term side-effects of chemotherapy in patients treated for non-epithelial ovarian cancer: national case-control protocol study of the GINECO-Vivrovaire rare tumors INCa French network for rare malignant ovarian tumors”
- Author
-
Gernier, François, Ahmed-Lecheheb, Djihane, Pautier, Patricia, Floquet, Anne, Nadeau, Cédric, Frank, Sophie, Alexandre, Jérôme, Selle, Frédéric, Berton-Rigaud, Dominique, Kalbacher, Elsa, Orfeuvre, Hubert, Lortholary, Alain, Augereau, Paule, Labombarda, Fabien, Perrier, Lionel, Grellard, Jean-Michel, Licaj, Idlir, Clarisse, Bénédicte, Savoye, Aude-Marie, Bourien, Héloise, De La Motte Rouge, Thibaut, Kurtz, Jean-Emmanuel, Kerdja, Katia, Lelaidier, Anaïs, Charreton, Amandine, Ray-Coquard, Isabelle, and Joly, Florence
- Published
- 2021
- Full Text
- View/download PDF
8. Beyond the map: evidencing the spatial dimension of health inequalities
- Author
-
Fayet, Yohan, Praud, Delphine, Fervers, Béatrice, Ray-Coquard, Isabelle, Blay, Jean-Yves, Ducimetiere, Françoise, Fagherazzi, Guy, and Faure, Elodie
- Published
- 2020
- Full Text
- View/download PDF
9. Incidence and time trends of sarcoma (2000–2013): results from the French network of cancer registries (FRANCIM)
- Author
-
Amadeo, Brice, Penel, Nicolas, Coindre, Jean-Michel, Ray-Coquard, Isabelle, Ligier, Karine, Delafosse, Patricia, Bouvier, Anne-Marie, Plouvier, Sandrine, Gallet, Justine, Lacourt, Aude, Coureau, Gaëlle, Monnereau, Alain, Mathoulin-Pélissier, Simone, and Desandes, Emmanuel
- Published
- 2020
- Full Text
- View/download PDF
10. Development of a disease-specific graded prognostic assessment index for the management of sarcoma patients with brain metastases (Sarcoma-GPA)
- Author
-
Patrikidou, Anna, Chaigneau, Loic, Isambert, Nicolas, Kitikidou, Kyriaki, Shanley, Ryan, Ray-Coquard, Isabelle, Valentin, Thibaud, Malivoir, Bettina, Laigre, Maryline, Bay, Jacques-Olivier, Moureau-Zabotto, Laurence, Bompas, Emmanuelle, Piperno-Neumann, Sophie, Penel, Nicolas, Alcindor, Thierry, Guillemet, Cécile, Duffaud, Florence, Hügli, Anne, Le Pechoux, Cécile, Dhermain, Frédéric, Blay, Jean-Yves, Sperduto, Paul W., and Le Cesne, Axel
- Published
- 2020
- Full Text
- View/download PDF
11. Lymphopenia in Cancer Patients and its Effects on Response to Immunotherapy: an opportunity for combination with Cytokines?
- Author
-
Ménétrier-Caux, Christine, Ray-Coquard, Isabelle, Blay, Jean-Yves, and Caux, Christophe
- Published
- 2019
- Full Text
- View/download PDF
12. Prognostic and predictive factors for angiosarcoma patients receiving paclitaxel once weekly plus or minus bevacizumab: an ancillary study derived from a randomized clinical trial
- Author
-
Lebellec, Loïc, Bertucci, François, Tresch-Bruneel, Emmanuelle, Ray-Coquard, Isabelle, Le Cesne, Axel, Bompas, Emmanuelle, Blay, Jean-Yves, Italiano, Antoine, Mir, Olivier, Ryckewaert, Thomas, Toiron, Yves, Camoin, Luc, Goncalves, Anthony, Penel, Nicolas, and Le Deley, Marie-Cécile
- Published
- 2018
- Full Text
- View/download PDF
13. Being treated in higher volume hospitals leads to longer progression-free survival for epithelial ovarian carcinoma patients in the Rhone-Alpes region of France.
- Author
-
Huguet, Marius, Perrier, Lionel, Bally, Olivia, Benayoun, David, De Saint Hilaire, Pierre, Beal Ardisson, Dominique, Morelle, Magali, Havet, Nathalie, Joutard, Xavier, Meeus, Pierre, Gabelle, Philippe, Provençal, Jocelyne, Chauleur, Céline, Glehen, Olivier, Charreton, Amandine, Farsi, Fadila, and Ray-Coquard, Isabelle
- Subjects
OVARIAN epithelial cancer ,PROGRESSION-free survival ,HOSPITAL care ,SURGICAL excision ,MEDICAL care ,CANCER treatment ,OVARIAN tumors ,EPITHELIAL cell tumors ,COMPARATIVE studies ,DATABASES ,HOSPITALS ,RESEARCH methodology ,MEDICAL cooperation ,PROGNOSIS ,RESEARCH ,RESEARCH funding ,EVALUATION research ,TREATMENT effectiveness ,RETROSPECTIVE studies ,TUMOR treatment - Abstract
Background: To investigate the relationship between hospital volume activities and the survival for Epithelial Ovarian Carcinoma (EOC) patients in France.Methods: This retrospective study using prospectively implemented databases was conducted on an exhaustive cohort of 267 patients undergoing first-line therapy during 2012 in the Rhone-Alpes Region of France. We compared Progression-Free Survival for Epithelial Ovarian Carcinoma patients receiving first-line therapy in high- (i.e. ≥ 12 cases/year) vs. low-volume hospitals. To control for selection bias, multivariate analysis and propensity scores were used. An adjusted Kaplan-Meier estimator and a univariate Cox model weighted by the propensity score were applied.Results: Patients treated in the low-volume hospitals had a probability of relapse (including death) that was almost two times (i.e. 1.94) higher than for patients treated in the high-volume hospitals (p < 0.001).Conclusion: To our knowledge, this is the first study conducted in this setting in France. As reported in other countries, there was a significant positive association between greater volume of hospital care for EOC and patient survival. Other factors may also be important such as the quality of the surgical resection. [ABSTRACT FROM AUTHOR]- Published
- 2018
- Full Text
- View/download PDF
14. Antiangiogenic effects in patients with progressive desmoplastic small round cell tumor: data from the French national registry dedicated to the use of off-labeled targeted therapy in sarcoma (OUTC's).
- Author
-
Bétrian, Sarah, Bergeron, Christophe, Blay, Jean-Yves, Bompas, Emmanuelle, Cassier, Philippe A., Chevallier, Laure, Fayette, Jérome, Girodet, Magali, Guillemet, Cécile, Cesne, Axel Le, Marec-Berard, Perrine, Ray-Coquard, Isabelle, and Chevreau, Christine
- Subjects
DESMOPLASTIC small round cell tumor ,ABDOMINAL cancer ,CANCER chemotherapy ,DISEASES in women ,DATA analysis ,DIAGNOSIS ,CANCER treatment - Abstract
Background: Desmoplastic small round cell tumor (DSRCT) is a very rare mesenchymal tumor that mainly affects teenagers and young adults with a mean age at diagnosis around 20-25 years. Although initial management still needs standardization, many centers will use multimodal treatment including intensive chemotherapy, extensive surgical resection followed by radiotherapy. Despite this, prognosis remains very poor and the median overall survival is 25 months. Recurrent disease is mainly treated by chemotherapy. Recently, due to the unmet medical need for recurrent disease, targeted therapies were explored for DSRCT. Methods: In this study, we assessed the response rate and progression free survival in nine cases of progressive DSRCT included in the OUTC's registry and treated with antiangiogenics targeted agents (sunitinib, sorafenib and bevacizumab). OUTC's, a French national registry, collects data about the use of off-label targeted therapy in sarcoma. Results: Eight males and one woman were included, with median age at diagnosis of 27.3 years (range from 9 to 48 years). They received a mean 3 lines (2-5) of treatment before antiangiogenic agent initiation. Six patients received sunitinib, two received sorafenib and one bevacizumab. Median progression free survival was 3.1 months (range 2-5.5 months) and best response observed was 5.5 months stable disease. Most patients had manageable low-grade toxicities, mainly fatigue, abdominal pain and skin toxicity. Conclusions: Despite very limited activity of antiangiogenics in our study, prospective collection of cases of these rare tumors together with molecular data should guide therapeutic decision and enhance outcome. [ABSTRACT FROM AUTHOR]
- Published
- 2017
- Full Text
- View/download PDF
15. Patterns of care and outcomes of patients with METAstatic soft tissue SARComa in a real-life setting: the METASARC observational study.
- Author
-
Savina, Marion, Le Cesne, Axel, Blay, Jean-Yves, Ray-Coquard, Isabelle, Mir, Olivier, Toulmonde, Maud, Cousin, Sophie, Terrier, Philippe, Ranchere-Vince, Dominique, Meeus, Pierre, Stoeckle, Eberhard, Honoré, Charles, Sargos, Paul, Sunyach, Marie-Pierre, Le Péchoux, Cécile, Giraud, Antoine, Bellera, Carine, Le Loarer, François, and Italiano, Antoine
- Subjects
HEALTH outcome assessment ,METASTASIS ,CANCER treatment ,SARCOMA ,SCIENTIFIC observation ,CANCER chemotherapy ,MEDICAL personnel training ,ANTINEOPLASTIC agents ,DOXORUBICIN ,SOFT tissue tumors ,SURVIVAL analysis (Biometry) ,TREATMENT effectiveness ,LEIOMYOSARCOMA ,THERAPEUTICS ,TUMOR treatment - Abstract
Background: Well-designed observational studies of individuals with rare tumors are needed to improve patient care, clinical investigations, and the education of healthcare professionals.Methods: The patterns of care, outcomes, and prognostic factors of a cohort of 2225 patients with metastatic soft tissue sarcomas who were diagnosed between 1990 and 2013 and documented in the prospectively maintained database of the French Sarcoma Group were analyzed.Results: The median number of systemic treatments was 3 (range, 1-6); 27% of the patients did not receive any systemic treatment and 1054 (49%) patients underwent locoregional treatment of the metastasis. Half of the patients who underwent chemotherapy (n = 810) received an off-label drug. Leiomyosarcoma was associated with a significantly better outcome than the other histological subtypes. With the exception of leiomyosarcomas, the benefit of a greater than third-line regimen was very limited, with a median time to next treatment (TNT) and overall survival (OS) ranging between 2.3 and 3.7 months and 5.4 and 8.5 months, respectively. The TNT was highly correlated with OS. Female sex, leiomyosarcoma histology, locoregional treatment of metastases, inclusion in a clinical trial, and treatment with first-line polychemotherapy were significantly associated with improved OS in the multivariate analysis.Conclusions: The combination of doxorubicin with a second drug, such as ifosfamide, represents a valid option, particularly when tumor shrinkage is expected to provide clinical benefits. After failure of the second-line therapy, best supportive care should be considered, particularly in patients with non-leiomyosarcoma histology who are not eligible to participate in a clinical trial. Locoregional treatment of metastasis should always be included in the therapeutic strategy when feasible. TNT may represent a useful surrogate endpoint for OS in clinical studies. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
16. Treatment patterns and survival in an exhaustive French cohort of pazopanib-eligible patients with metastatic soft tissue sarcoma (STS).
- Author
-
Ray-Coquard, Isabelle, Collard, Olivier, Ducimetiere, Françoise, Laramas, Mathieu, Mercier, Florence, Ladarre, Nadine, Manson, Stephanie, Tehard, Bertrand, Clippe, Sébastien, Suchaud, Jean-Philippe, Stefani, Laetitia, and Blay, Jean-Yves
- Subjects
- *
SOFT tissue tumors , *RADIOTHERAPY , *PROGRESSION-free survival , *ANTINEOPLASTIC agents , *CANCER treatment , *HETEROCYCLIC compounds , *SULFONAMIDES , *LONGITUDINAL method , *SARCOMA , *TREATMENT effectiveness , *DIAGNOSIS , *THERAPEUTICS - Abstract
Background: The French EMS study prospectively collected exhaustive data from STS patients diagnosed in the Rhone-Alpes region from 2005 to 07.Methods: The database included diagnosis/histology, surgery, radiotherapy, systemic treatments and treatment response. Treatment patterns and outcomes of patients with metastatic disease, excluding adipocytic sarcoma and GIST were analyzed.Results: Of 888 total patients, 145 were included based on having metastatic disease and appropriate subtypes. All patients received treatment with systemic therapy being most common (74%, n = 107), followed by radiotherapy (30%, n = 44) and surgery (23%, n = 33). Doxorubicin, alone or in combination, was the most common first line systemic therapy (65%, n = 46). Drugs without license in sarcoma were used in 38-83% of treatments depending on treatment line. 24% of frontline patients demonstrated an objective response, decreasing to 11% objective responses in second line but no responses were documented beyond second line, with median PFS declining with each additional line. Median PFS also declined in patients receiving surgery compared to those receiving no surgery (8-15 m vs 5 m). Median OS from metastatic diagnosis for patients receiving systemic therapy was double that of patients without systemic treatment (24 m vs 12 m, p = 0.007).Conclusions: Outcomes in this population were poor and declined with successive treatment. However, results suggest that further anticancer therapies in recurrent sarcoma might be beneficial. [ABSTRACT FROM AUTHOR]- Published
- 2017
- Full Text
- View/download PDF
17. Off-label use of targeted therapies in osteosarcomas: data from the French registry OUTC'S (Observatoire de l'Utilisation des Thérapies Ciblées dans les Sarcomes).
- Author
-
Penel-Page, Mathilde, Ray-Coquard, Isabelle, Larcade, Julie, Girodet, Magali, Bouclier, Laure, Rogasik, Muriel, Corradini, Nadège, Entz-Werle, Natacha, Brugieres, Laurence, Domont, Julien, Lervat, Cyril, Piperno-Neumann, Sophie, Pacquement, Helène, Bay, Jacques-Olivier, Gentet, Jean-Claude, Thyss, Antoine, Chaigneau, Loic, Narciso, Bérangère, Cornille, Helène, and Blay, Jean-Yves
- Subjects
- *
OSTEOSARCOMA , *TARGETED drug delivery , *PROTEIN-tyrosine kinase inhibitors , *OFF-label use (Drugs) , *MTOR protein , *CANCER relapse , *RAPAMYCIN , *MULTIVARIATE analysis , *ANTINEOPLASTIC agents , *DRUG therapy , *LONGITUDINAL method , *MEDICAL prescriptions , *REOPERATION , *TUMOR classification , *TREATMENT effectiveness , *ACQUISITION of data , *TUMOR grading - Abstract
Background: The objective of this study is to explore the off-label use of targeted therapies (TTs) for patients with osteosarcoma registered within the French Sarcoma Group--Bone Tumor Study Group (GSF-GETO) national registry.Methods: All patients with an osteosarcoma, registered between January 1, 2009 and July 15, 2013 were analyzed.Results: Twenty-nine patients with refractory relapsed osteosarcomas received 33 treatment lines of TTs. The median age at the beginning of treatment was 19 years (range 9-72). The median number of previous lines of chemotherapy was 3 (range 1-8). Before inclusion, 3 patients were in second complete remission, 26 were in progression for metastatic relapse. Twenty-three patients received sirolimus (in combination with cyclophosphamide for 18); 5, sunitinib; 4, sorafenib; and one, pazopanib. Stable disease was observed for 45.5% of patients (95% Confidence Interval (CI) [20-52.8]). The median Progression-Free Survival (PFS) was 3 months (95% CI [2-5.4]) for patients treated by sirolimus and 1.8 months (95% CI [1.3-2.8]) for patients receiving multi-targeted tyrosine kinase inhibitors; 6-month PFS 15%. The median Overall Survival (OS) was 6.8 months (95% CI [4.7-12.1]), and one-year OS was 24%. In a multivariate analysis, PFS was superior for patients receiving sirolimus compared to other TTs (Hazard Ratio (HR) = 2.7, 95% CI [1.05-7.1]). No toxic death was reported. Grade 3 and 4 toxicities were observed in 27 and 6% of cases respectively.Conclusion: Off-label TTs, especially sirolimus, reported benefit in the treatment of refractory osteosarcomas with an acceptable toxicity profile, including in pediatric population. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
18. KIT exon 10 variant (c.1621 A > C) single nucleotide polymorphism as predictor of GIST patient outcome.
- Author
-
Brahmi, Mehdi, Alberti, Laurent, Dufresne, Armelle, Ray-Coquard, Isabelle, Cassier, Philippe, Meeus, Pierre, Decouvelaere, Anne-Valérie, Ranchère-Vince, Dominique, and Blay, Jean-Yves
- Subjects
HEALTH outcome assessment ,GENETIC polymorphisms ,EXONS (Genetics) ,GASTROINTESTINAL stromal tumors ,GENETICS ,PROGNOSIS ,DIAGNOSIS ,PATIENTS ,ANTINEOPLASTIC agents ,CELL lines ,MULTIVARIATE analysis ,PHOSPHORYLATION ,TRANSFERASES ,GASTROINTESTINAL tumors ,DISEASE relapse ,RETROSPECTIVE studies ,PROTEIN kinase inhibitors ,PHARMACODYNAMICS - Abstract
Background: Tumor genotype plays a crucial role in clinical management of GIST. Whether genetic polymorphism of KIT may influence GIST patient outcome is unclear.Methods: We investigated the biological and clinical significance of the presence of KIT exon 10 variant (c.1621 A > C), KIT (L541), in a transfected cell line (3 T3 L541) and in two retrospectively collected series of 109 GIST patients in total. The control group consisted of 60 healthy donors collected at the French department of blood transfusion.Results: In the 3 T3 L541 cell line, KIT(L541) protein exhibited a spontaneous phosphorylation status comparable to that of wild-type KIT but displayed a phosphorylation pattern of AKT and ERK1/2 that was found similar to that of the classical mutated forms of the KIT receptor. Of 109 patients enrolled in this retrospective translational research study, 24 (22%) harboured KIT (L541), similarly to the control group of healthy donors (n = 10 of 60, 17%). A higher prevalence of the variant KIT (L541) was observed in patients with metastatic status at diagnosis (KIT (L541) correlated nine of 22 versus 15 of 87, p = 0.02). In addition, patients with KIT (L541) and localized GIST had a higher rate of relapse at 5 years and lower relapse free survival at 5 years in univariate, as well as in multivariate analysis. Response rate and duration of response to imatinib was similar in KIT (L541) and KIT (M541) patients.Conclusion: KIT (L541) genotype is associated with a higher risk of metastasis at diagnosis and a higher risk of relapse in GIST patients. [ABSTRACT FROM AUTHOR]- Published
- 2015
- Full Text
- View/download PDF
19. Transferability of health cost evaluation across locations in oncology: cluster and principal component analysis as an explorative tool.
- Author
-
Perrier, Lionel, Buja, Alessandra, Mastrangelo, Giuseppe, Baron, Patrick Sylvestre, Ducimetière, Françoise, Pauwels, Petrus J., Rossi, Carlo Riccardo, Gilly, François Noël, Martin, Amaury, Favier, Bertrand, Farsi, Fadila, Laramas, Mathieu, Baldo, Vincenzo, Collard, Olivier, Cellier, Dominic, Blay, Jean-Yves, and Ray-Coquard, Isabelle
- Abstract
Background The transferability of economic evaluation in health care is of increasing interest in today’s globalized environment. Here, we propose a methodology for assessing the variability of data elements in cost evaluations in oncology. This method was tested in the context of the European Network of Excellence “Connective Tissues Cancers Network”. Methods Using a database that was previously aimed at exploring sarcoma management practices in Rhône-Alpes (France) and Veneto (Italy), we developed a model to assess the transferability of health cost evaluation across different locations. A nested data structure with 60 final factors of variability (e.g., unit cost of chest radiograph) within 16 variability areas (e.g., unit cost of imaging) within 12 objects (e.g., diagnoses) was produced in Italy and France, separately. Distances between objects were measured by Euclidean distance, Mahalanobis distance, and city-block metric. A hierarchical structure using cluster analysis (CA) was constructed. The objects were also represented by their projections and area of variability through correlation studies using principal component analysis (PCA). Finally, a hierarchical clustering based on principal components was performed. Results CA suggested four clusters of objects: chemotherapy in France; follow-up with relapse in Italy; diagnosis, surgery, radiotherapy, chemotherapy, and follow-up without relapse in Italy; and diagnosis, surgery, and follow-up with or without relapse in France. The variability between clusters was high, suggesting a lower transferability of results. Also, PCA showed a high variability (i.e. lower transferability) for diagnosis between both countries with regard to the quantities and unit costs of biopsies. Conclusion CA and PCA were found to be useful for assessing the variability of cost evaluations across countries. In future studies, regression methods could be applied after these methods to elucidate the determinants of the differences found in these analyses. [ABSTRACT FROM AUTHOR]
- Published
- 2014
- Full Text
- View/download PDF
20. Outcome of patients with advanced solitary fibrous tumors: the Centre Léon Bérard experience.
- Author
-
Levard, Alice, Derbel, Olfa, Méeus, Pierre, Ranchère, Dominique, Ray-Coquard, Isabelle, Blay, Jean-Yves, and Cassier, Philippe A
- Subjects
DRUG therapy ,SOFT tissue tumors ,CANCER chemotherapy ,VASCULAR endothelial growth factors ,PHARMACOLOGY - Abstract
Background: Solitary Fibrous Tumor is a rare type of soft tissue tumor of intermediate malignant potential which may recur or metastasize in 15-20% of cases. Data on the management of patients with advanced SFT is scarce: chemotherapy has been described as ineffective, while recent data suggests that anti-angiogenic therapies may be more efficient. Methods: We conducted a retrospective study on patients treated for advanced SFT at a single institution: from January 1994 to December 2011, 30 patients were treated in the Centre Léon Bérard for an advanced SFT. Results: Twenty-three patients received cytotoxic chemotherapy as first-line therapy. Best responses were 2 (9%) partial responses, 13 (57%) stable diseases (SD) and 8 (35%) progressive diseases (PD). Median Progression Free Survival (PFS) was 5.2 (95% CI: 3.2-7.1) months and 9 patients were free of progression at 6 months. Ten patients received an anti-angiogenic treatment (sunitinib or pazopanib) as a 2
nd , 3rd or 4th line. Best responses were 5 SD and 5 PD; median PFS was 5.1 months (95% CI 0.7-9.6). Four patients (36%) were progression-free for more than 6 months. Two patients receiving pazopanib were without progression at 6 and 8 months and two patients receiving sunitinib were free of progression at 30 months. Conclusion: Response rate with standard chemotherapy was low and PFS appear similar between cytotoxic chemotherapy and anti-angiogenic agents. [ABSTRACT FROM AUTHOR]- Published
- 2013
- Full Text
- View/download PDF
21. Long-term outcome and effect of maintenance therapy in patients with advanced sarcoma treated with trabectedin: an analysis of 181 patients of the French ATU compassionate use program.
- Author
-
Blay, Jean-Yves, Italiano, Antoine, Ray-Coquard, Isabelle, Cesne, Axel Le, Duffaud, Florence, Rios, Maria, Collard, Olivier, Bertucci, François, Bompas, Emmanuelle, Isambert, Nicolas, Chaigneau, Loic, Cassier, Philippe, Bui, Binh, Decanter, Gauthier, Derbel, Olfa, Coindre, Jean-Michel, Zintl, Patrick, Badri, Nadia, and Penel, Nicolas
- Subjects
CLINICAL medicine ,TRABECTEDIN ,SARCOMA ,DOXORUBICIN ,CLINICAL trials ,THERAPEUTICS - Abstract
Background: The long term outcome of advanced sarcoma patients treated with trabectedin outside of clinical trials and the utility of maintenance treatment has not been reported. Methods: Between 2003 and 2008, patients with advanced sarcoma failing doxorubicin could be treated within a compassionate use program (ATU, Temporary Use Authorization) of trabectedin in France using the standard 3-weekly regimen. Data from 181 patients (55%) were collected from 11 centres and analyzed. Results: Trabectedin was given in first, second, third or fourth line in metastatic phase in 6%, 37%, 33% and 23% of patients respectively. With a median follow-up of 6 years, median PFS and OS were 3.6 months and 16.1 months respectively. The median number of cycles was 3 (range 1-19). Best response were partial response (PR, n = 18, 10%), stable disease (SD, n = 69, 39%) and progressive disease (PD, n = 83, 46%), non evaluable (NE, n = 9, 5%). Thirty patients (17%) had to be hospitalized for treatment- related side effects. Independent prognostic factors in multivariate analysis (Cox model) were myxoid LPS and line of trabectedin for PFS, and myxoid LPS and retroperitoneal sarcomas for OS. Patients in PR or SD after 6 cycles continuing treatment had a better PFS (median 5.3 vs 10.5 months, p = 0.001) and OS (median 13.9 vs 33.4 months, p = 0.009) as compared to patients who stopped after 6 cycles. Conclusions: In this compassionate use program, trabectedin yielded similar or better PFS and OS than in clinical trials. Maintenance treatment beyond 6 cycles was associated with an improved survival. [ABSTRACT FROM AUTHOR]
- Published
- 2013
- Full Text
- View/download PDF
22. Can treatment with Cocculine improve the control of chemotherapy-induced emesis in early breast cancer patients? A randomized, multi-centered, double-blind, placebo-controlled Phase III trial.
- Author
-
Pérol, David, Provençal, Jocelyne, Hardy-Bessard, Anne-claire, Coeffic, David, Jacquin, Jean-Phillipe, Agostini, Cécile, Bachelot, Thomas, Guastalla, Jean-Paul, Pivot, Xavier, Martin, Jean-Pierre, Bajard, Agathe, and Ray-Coquard, Isabelle
- Subjects
PHYSIOLOGICAL effects of chemotherapy ,VOMITING prevention ,QUALITY of life ,BREAST cancer patients ,BREAST cancer treatment ,TREATMENT effectiveness - Abstract
Background: Chemotherapy induced nausea and vomiting (CINV) remains a major problem that seriously impairs the quality of life (QoL) in cancer patients receiving chemotherapy regimens. Complementary medicines, including homeopathy, are used by many patients with cancer, usually alongside with conventional treatment. A randomized, placebo-controlled Phase III study was conducted to evaluate the efficacy of a complex homeopathic medicine, Cocculine, in the control of CINV in non-metastatic breast cancer patients treated by standard chemotherapy regimens. Methods: Chemotherapy-naïve patients with non-metastatic breast cancer scheduled to receive 6 cycles of chemotherapy including at least three initial cycles of FAC 50, FEC 100 or TAC were randomized to receive standard anti-emetic treatment plus either a complex homeopathic remedy (Cocculine, registered in France for treatment of nausea and travel sickness) or the matching placebo (NCT00409071 clinicaltrials.gov). The primary endpoint was nausea score measured after the 1st chemotherapy course using the FLIE questionnaire (Functional Living Index for Emesis) with 5-day recall. Secondary endpoints were: vomiting measured by the FLIE score, nausea and vomiting measured by patient self-evaluation (EVA) and investigator recording (NCI-CTC AE V3.0) and treatment compliance. Results: From September 2005 to January 2008, 431 patients were randomized: 214 to Cocculine (C) and 217 to placebo (P). Patient characteristics were well-balanced between the 2 arms. Overall, compliance to study treatments was excellent and similar between the 2 arms. A total of 205 patients (50.9%; 103 patients in the placebo and 102 in the homeopathy arms) had nausea FLIE scores > 6 indicative of no impact of nausea on quality of life during the 1st chemotherapy course. There was no difference between the 2 arms when primary endpoint analysis was performed by chemotherapy stratum; or in the subgroup of patients with susceptibility to nausea and vomiting before inclusion. In addition, nausea, vomiting and global emesis FLIE scores were not statistically different at any time between the two study arms. The frequencies of severe (Grade = 2) nausea and vomiting were low in our study (nausea: P: 17.6% vs C: 15.7%, p=0.62; vomiting: P: 10.8% vs C: 12.0%, p=0.72 during the first course). Conclusion: This double-blinded, placebo-controlled, randomised Phase III study showed that adding a complex homeopathic medicine (Cocculine) to standard anti-emetic prophylaxis does not improve the control of CINV in early breast cancer patients. [ABSTRACT FROM AUTHOR]
- Published
- 2012
- Full Text
- View/download PDF
23. Validation of prognostic scores for survival in cancer patients beyond first-line therapy.
- Author
-
Trédan, Olivier, Ray-Coquard, Isabelle, Chvetzoff, Gisèle, Rebattu, Paul, Bajard, Agathe, Chabaud, Sylvie, Pérol, David, Saba, Chadi, Quiblier, Florent, Blay, Jean-Yves, and Bachelot, Thomas
- Subjects
- *
CANCER patients , *DRUG therapy , *METASTASIS , *LACTATE dehydrogenase , *LYMPHOCYTES - Abstract
Background: We aimed to validate prognostic scores for survival in patients undergoing chemotherapy for advanced or metastatic cancer after first-line treatment. Methods: We previously described two models with good prognostic value based on a combination of Performance Status (PS) and either lactate dehydrogenase (LDH) level or lymphocyte count. These factors were evaluated for their ability to predict overall survival (OS) in a prospective cohort of 299 patients. Clinical and blood parameters were prospectively recorded. Candidate prognostic factors for OS with 0.05 significance level in univariate analysis were included in a multivariate Cox model. Results: Median age was 59 years (range: 26-85). Primary tumor sites were breast (45%), lung (15%), ovaries (11%) and others (29%). The number of metastatic sites was 1 (29%), 2 (48%), >2 (23%). Median follow-up and median OS were 12 and 6 months, respectively. Multiple regression analysis confirmed that PS >1, lymphocyte count ≤700/μL and LDH >600 UI/L were independent predictors of short OS, as well as interleukin 6 (IL-6) level, serum albumin concentration and platelet count. Conclusions: Prognostic scores using PS plus LDH level or PS plus lymphocyte count were validated for predicting survival in metastatic cancer patients in relapse beyond first-line treatment. A score combining PS, LDH, lymphocyte and platelet count, serum albumin and IL-6 level was superior in determining patients' prognosis. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
24. Prognostic value of the expression of C-Chemokine Receptor 6 and 7 and their ligands in non-metastatic breast cancer.
- Author
-
Cassier, Philippe A., Treilleux, Isabelle, Bachelot, Thomas, Ray-Coquard, Isabelle, Bendriss-Vermare, Nathalie, Ménétrier-Caux, Christine, Trédan, Olivier, Goddard-Léon, Sophie, Pin, Jean-Jacques, Mignotte, Hervé, Bathélémy-Dubois, Clarisse, Caux, Christophe, Lebecque, Serge, and Blay, Jean-Yves
- Subjects
CHEMOKINES ,LIGANDS (Biochemistry) ,BREAST cancer ,LEUCOCYTES ,CANCER cells - Abstract
Background: Chemokines and chemokine receptors are major actors of leukocytes trafficking and some have been shown to play an important role in cancer metastasis. Chemokines CCL19, CCL20 and CCL21 and their receptors CCR6 and CCR7, were assessed as potential biomarkers of metastatic dissemination in primary breast cancer. Methods: Biomarker expression levels were evaluated using immunohistochemistry on paraffin-embedded tissue sections of breast cancer (n = 207). Results: CCR6 was expressed by tumor cells in 35% of cases. CCR7 was expressed by spindle shaped stromal cells in 43% of cases but not by tumor cells in this series. CCL19 was the only chemokine found expressed in a significant number of breast cancers and was expressed by both tumor cells and dendritic cells (DC). CCR6, CCL19 and CCR7 expression correlated with histologic features of aggressive disease. CCR6 expression was associated with shorter relapse-free survival (RFS) in univariate and but not in multivariate analysis (p = 0.0316 and 0.055 respectively), and was not associated with shorter overall survival (OS). Expression of CCR7 was not significantly associated with shorter RFS or OS. The presence of CCL19-expressing DC was associated with shorter RFS in univariate and multivariate analysis (p = 0.042 and 0.020 respectively) but not with shorter OS. Conclusion: These results suggest a contribution of CCR6 expression on tumor cells and CCL19-expressing DC in breast cancer dissemination. In our series, unlike what was previously published, CCR7 was exclusively expressed on stromal cells and was not associated with survival. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
25. Neoadjuvant imatinib in patients with locally advanced non metastatic GIST in the prospective BFR14 trial.
- Author
-
Blesius, Aurore, Cassier, Philippe A., Bertucci, François, Fayette, Jerome, Ray-Coquard, Isabelle, Bui, Binh, Adenis, Antoine, Rios, Maria, Cupissol, Didier, Pérol, David, Blay, Jean-Yves, and Le Cesne, Axel
- Subjects
IMATINIB ,GASTROINTESTINAL stromal tumors ,MYELOID leukemia ,PROTEIN-tyrosine kinases ,IMMUNOHISTOCHEMISTRY - Abstract
Background: The role of surgery in the management of patients with advanced gastrointestinal stromal tumors (GIST) in the era of imatinib mesylate (IM) remains debated. We analyzed the outcome of patients with non metastatic locally advanced primary GIST treated with IM within the prospective BFR14 phase III trial. Methods: The database of the BFR14 trial was searched for patients with no metastasis at time of inclusion. Patients treated for recurrent disease were excluded. Twenty-five of 434 patients met these criteria. Results: Fifteen of 25 patients (60%) had a partial response to IM. Nine of the 25 patients (36%) underwent surgical resection of their primary tumor after a median of 7.3 months of IM treatment (range 3.4-12.0). Per protocol patients received continuous IM treatment in the post resection period, in an adjuvant setting. With a median follow-up of 53.5 months, there was a significant improvement in progression-free survival (PFS) and overall survival (OS) for patients who underwent surgical resection versus those who did not (median not reached vs 23.6 months, p = 0.0318 for PFS and median not reached vs 42.2 months, p = 0.0217 for OS). In the group of patients who underwent resection followed by IM, the 3-year PFS and OS rates were 67% and 89% respectively Conclusions: Following neoadjuvant IM for non metastatic locally advanced GIST 9 of 25 patients (36%) were selected for resection of the primary tumor. OS and PFS figures were close to those of localised intermediate or high risk GIST (70% at 5 years) in the subgroup of operated patients, while the outcome of the non-operated subgroup was similar to that of metastatic GIST. [ABSTRACT FROM AUTHOR]
- Published
- 2011
- Full Text
- View/download PDF
26. Factors of interrupting chemotherapy in patientswith Advanced Non-Small-Cell Lung Cancer.
- Author
-
Belbaraka, Rhizlane, Trédan, Olivier, Ray-Coquard, Isabelle, Chvetzoff, Giselle, Bajard, Agathe, Pérol, David, Ismaili, Nabil, Ismaili, Mohammed, Errihani, Hassan, Bachelot, Thomas, and Rebattu, Paul
- Subjects
MEDICAL research ,LUNG cancer ,DRUG therapy ,CANCER patients ,CANCER treatment ,DISEASE complications ,HEMOGLOBIN polymorphisms ,CLINICAL medicine ,SMALL cell lung cancer ,HEMOGLOBINS - Abstract
Background: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic factors. In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified. Findings: Forty-five patients that were previously treated for metastatic disease from 12/2000 to 11/2005 in the comprehensive cancer centre (Centre Léon Bérard). Clinical assessment and blood parameters were recorded and considered. Patient prognostic factors for overall survival (OS) with a 0.05-significance level in univariate analysis were entered in a multivariate Cox model for further analysis. Patients' median age was 58.5 years (range: 37 - 76). Sixty two percent of the patients were PS = 0 or 1. After inclusion, nine patients received second-line (22.5%), and two received third-line chemotherapy (5%). Univariate analysis showed that the factors associated with reduced OS were: PS > 2, weight loss >10%, more than one line of chemotherapy treatment and abnormal blood parameters (hemoglobin (Hb), platelet and neutrophils counts). Multiple regression analysis confirmed that PS > 2 and abnormal hemoglobin were independent predictors for low overall survival. According to the presence of none (33%), 1 (37%) and 2 (30%) prognostic factors, median OS were 12, 5 and 2 months respectively. Conclusion: From this prospective study, both PS and anemia were found as independent determinants of survival, we found that both PS and anemia were independent determinants of survival. The combination of poor PS and anemia is an effective strategy to predict survival in the case of patients with metastatic NSCLC receiving further treatment after the first line. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
27. Epidemiological evaluation of concordancebetween initial diagnosis and central pathologyreview in a comprehensive and prospective seriesof sarcoma patients in the Rhone-Alpes region.
- Author
-
Lurkin, Antoine, Ducimetière, Francoise, Vince, Dominique Ranchère, Decouvelaere, Anne-Valérie, Cellier, Dominic, Gilly, François N., Salameire, Dimitri, Biron, Pierre, de Laroche, Guy, Blay, Jean Yves, and Ray-Coquard, Isabelle
- Subjects
SARCOMA ,CANCER ,PREVENTIVE medicine ,EPIDEMIOLOGY ,PUBLIC health ,HEALTH & welfare funds - Abstract
Background: Sarcomas are rare malignant tumors. Accurate initial histological diagnosis is essential for adequate management. We prospectively assessed the medical management of all patients diagnosed with sarcoma in a European region over a one-year period to identify the quantity of first diagnosis compared to central expert review (CER). Methods: Histological data of all patients diagnosed with sarcoma in Rhone-Alpes between March 2005 and Feb 2006 were collected. Primary diagnoses were systematically compared with second opinion from regional and national experts. Results: Of 448 patients included, 366 (82%) matched the inclusion criteria and were analyzed. Of these, 199 (54%) had full concordance between primary diagnosis and second opinion (the first pathologist and the expert reached identical conclusions), 97 (27%) had partial concordance (identical diagnosis of conjonctive tumor but different grade or subtype), and 70 (19%) had complete discordance (different histological type or invalidation of the diagnosis of sarcoma). The major discrepancies were related to histological grade (n = 68, 19%), histological type (n = 39, 11%), subtype (n = 17, 5%), and grade plus subtype or grade plus histological type (n = 43, 12%). Conclusions: Over 45% of first histological diagnoses were modified at second reading, possibly resulting in different treatment decisions. Systematic second expert opinion improves the quality of diagnosis and possibly the management of patients. [ABSTRACT FROM AUTHOR]
- Published
- 2010
- Full Text
- View/download PDF
28. The off-label use of targeted therapies in sarcomas: the OUTC'S program.
- Author
-
Eberst L, Cropet C, Le Cesne A, Pautier P, Penel N, Adenis A, Chevreau C, Bay JO, Collard O, Cupissol D, Duffaud F, Gentet JC, Piperno-Neumann S, Marec-Berard P, Bompas E, Thyss A, Chaigneau L, Cassier P, Bertucci F, Blay JY, and Ray-Coquard I
- Subjects
- Adolescent, Adult, Aged, Antineoplastic Agents adverse effects, Cyclophosphamide adverse effects, Cyclophosphamide therapeutic use, Disease-Free Survival, Drug Delivery Systems, Female, Humans, Indoles adverse effects, Indoles therapeutic use, Male, Middle Aged, Niacinamide adverse effects, Niacinamide analogs & derivatives, Niacinamide therapeutic use, Phenylurea Compounds adverse effects, Phenylurea Compounds therapeutic use, Pyrroles adverse effects, Pyrroles therapeutic use, Registries, Sarcoma pathology, Sirolimus adverse effects, Sirolimus therapeutic use, Sorafenib, Sunitinib, Treatment Outcome, Young Adult, Antineoplastic Agents therapeutic use, Off-Label Use, Sarcoma drug therapy
- Abstract
Background: Few targeted therapies (TTs) are registered for sarcoma treatment despite numerous phase II studies and yet there are potential treatment options for patients after standard treatment escape. The French Sarcoma Group - Bone Tumor Study Group (GSF-GETO) created a national registry to evaluate the outcome of patients treated with off-label TTs., Methods: Every consecutive sarcoma-patient receiving an off-label TT outside a clinical trial was included. The objective was to describe this patient efficacy and safety data in routine practice., Results: From October 2008 to October 2011, 249 patients in 24 centers received 278 treatment lines with TTs. Twenty-five histological subtypes were included: most frequent were leiomyosarcoma (n=48, receiving sorafenib in 63%, and sunitinib in 27%), GIST (n=39, receiving sorafenib in 79%), and angiosarcoma (n=18, receiving sorafenib in 78%). The overall response rate to TTs was 15% (95% CI [10,6-20,2]), the disease control rate at 2 months was 59%. The median progression-free survival was 4,1 months (IC 95% [3,2-4,8]). Three complete responses were observed. No toxic death occurred, grade 3 and 4 toxicities were reported in 74 (27%) and 14 patients (5%) respectively., Conclusion: Off-label TTs can be used for sarcoma patients in routine practice with an acceptable toxicity profile and efficacy similar to that reported in non-randomized clinical trials.
- Published
- 2014
- Full Text
- View/download PDF
29. Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib: an active agent only in non progressive patients.
- Author
-
Duffaud F, Even C, Ray-Coquard I, Bompas E, Khoa-Huynh T, Salas S, Cassier P, Dufresne A, Bonvalot S, Ducimetiere F, Le Cesne A, and Blay JY
- Abstract
Unlabelled: Recombinant erythropoietin for the anaemia of patients with advanced Gastrointestinal Stromal Tumours (GIST) receiving imatinib : an active agent only in non progressive patients., Background: Imatinib is a standard treatment for advanced/metastatic GIST and in adjuvant setting. Anaemia is frequently observed in patients with advanced GIST, and is one of the most frequent side effects of imatinib with grade 3-4 anaemia in 10% of patients. Whether EPO treatment is useful in the management of GIST patients receiving imatinib treatment is unknown., Methods: A retrospective study of EPO treatment in GIST patients receiving imatinib was undertaken in 4 centres. Thirty four patients received EPO treatment among the 319 GIST patients treated with imatinib in clinical trials or with compassionate use between 2001 and 2003. The efficacy of EPO on the anaemia of patients with GIST treated with imatinib was analyzed., Results: There were 18 males and 16 females with a median age of 59 years. Median WHO-PS was 1. Primary tumour sites were mainly gastric (32%) and small bowel (29%). Sites of metastases were mainly liver (82%) and peritoneum (79%). The median delay between the initiation of imatinib treatment and EPO was 58 days (range 0-553). Median haemoglobin (Hb) level prior to EPO was 9 g/dL (range 6,9-11,8) and 11,7 g/dL (range 6,8-14,4) after 2 months. An increase of more than 2 g/dL was observed in 18 (53%) of patients. None of the 7 patients who progressed (PD) under imatinib treatment (400 mg/day) experienced HB response, as compared to 66% (18/27) of the remaining patients (PR + SD) (p = 0,002). Primary tumour site, liver metastases, peritoneal metastases, age, gender did not correlate with HB response to EPO. Response to EPO was observed in 2/11 patients receiving high-dose imatinib (800 mg/day) vs 16/23 of others. Using logistic regression, only PD before EPO treatment was retained as a predictive factor for EPO response., Conclusion: EPO enables to increase Hb in most anaemic GIST patients who do not progress under imatinib, but not in patients with progressive disease.
- Published
- 2012
- Full Text
- View/download PDF
30. Clinicians' adherence versus non adherence to practice guidelines in the management of patients with sarcoma: a cost-effectiveness assessment in two European regions.
- Author
-
Perrier L, Buja A, Mastrangelo G, Vecchiato A, Sandonà P, Ducimetière F, Blay JY, Gilly FN, Siani C, Biron P, Ranchère-Vince D, Decouvelaere AV, Thiesse P, Bergeron C, Dei Tos AP, Coindre JM, Rossi CR, and Ray-Coquard I
- Subjects
- Aged, Catchment Area, Health, Cost-Benefit Analysis, Disease-Free Survival, Drug Administration Schedule, Female, France, Humans, Italy, Male, Middle Aged, Neoplasm Staging, Outcome and Process Assessment, Health Care standards, Practice Patterns, Physicians' statistics & numerical data, Retrospective Studies, Sarcoma diagnosis, Sarcoma economics, Soft Tissue Neoplasms diagnosis, Soft Tissue Neoplasms economics, Soft Tissue Neoplasms pathology, Soft Tissue Neoplasms therapy, Tumor Burden, Guideline Adherence standards, Outcome and Process Assessment, Health Care economics, Practice Guidelines as Topic standards, Practice Patterns, Physicians' standards, Sarcoma therapy
- Abstract
Background: Although the management of sarcoma is improving, non adherence to clinical practice guidelines (CPGs) remains high, mainly because of the low incidence of the disease and the variety of histological subtypes. Since little is known about the health economics of sarcoma, we undertook a cost-effectiveness analysis (within the CONnective TIssue CAncer NETwork, CONTICANET) comparing costs and outcomes when clinicians adhered to CPGs and when they did not., Methods: Patients studied had a histological diagnosis of sarcoma, were older than 15 years, and had been treated in the Rhône-Alpes region of France (in 2005/2006) or in the Veneto region of Italy (in 2007). Data collected retrospectively for the three years after diagnosis were used to determine relapse free survival and health costs (adopting the hospital's perspective and a microcosting approach). All costs were expressed in euros (€) at their 2009 value. A 4% annual discount rate was applied to both costs and effects. The incremental cost-effectiveness ratio (ICER) was expressed as cost per relapse-free year gained when management was compliant with CPGs compared with when it was not. To capture uncertainty surrounding ICER, a probabilistic sensitivity analysis was performed based on a non-parametric bootstrap method., Results: A total of 219 patients were included in the study. Compliance with CPGs was observed for 118 patients (54%). Average total costs reached 23,571 euros when treatment was in accordance with CPGs and 27,313 euros when it was not. In relation to relapse-free survival, compliance with CPGs strictly dominates non compliance, i.e. it is both less costly and more effective. Taking uncertainty into account, the probability that compliance with CPGs still strictly dominates was 75%., Conclusions: Our findings should encourage physicians to increase their compliance with CPGs and healthcare administrators to invest in the implementation of CPGs in the management of sarcoma.
- Published
- 2012
- Full Text
- View/download PDF
31. Factors of interrupting chemotherapy in patients with Advanced Non-Small-Cell Lung Cancer.
- Author
-
Belbaraka R, Trédan O, Ray-Coquard I, Chvetzoff G, Bajard A, Pérol D, Ismaili N, Ismaili M, Errihani H, Bachelot T, and Rebattu P
- Abstract
Background: Little is known about prognosis of metastatic patients after receiving a first-line treatment and failure. Our group already showed in pre-treated patients enrolled in phase I clinical trials that a performance status (PS) > 2 and an LDH > 600 UI/L were independent prognostic factors. In this prospective study, which included 45 patients, we identified clinical and biological variables as outcome predictors in metastatic Non-Small Cell lung cancer after first line chemotherapy were identified., Findings: Forty-five patients that were previously treated for metastatic disease from 12/2000 to 11/2005 in the comprehensive cancer centre (Centre Léon Bérard). Clinical assessment and blood parameters were recorded and considered. Patient prognostic factors for overall survival (OS) with a 0.05-significance level in univariate analysis were entered in a multivariate Cox model for further analysis.Patients' median age was 58.5 years (range: 37 - 76). Sixty two percent of the patients were PS = 0 or 1. After inclusion, nine patients received second-line (22.5%), and two received third-line chemotherapy (5%). Univariate analysis showed that the factors associated with reduced OS were: PS > 2, weight loss >10%, more than one line of chemotherapy treatment and abnormal blood parameters (hemoglobin (Hb), platelet and neutrophils counts). Multiple regression analysis confirmed that PS > 2 and abnormal hemoglobin were independent predictors for low overall survival. According to the presence of none (33%), 1 (37%) and 2 (30%) prognostic factors, median OS were 12, 5 and 2 months respectively., Conclusion: From this prospective study, both PS and anemia were found as independent determinants of survival, we found that both PS and anemia were independent determinants of survival. The combination of poor PS and anemia is an effective strategy to predict survival in the case of patients with metastatic NSCLC receiving further treatment after the first line.
- Published
- 2010
- Full Text
- View/download PDF
32. Epidemiological evaluation of concordance between initial diagnosis and central pathology review in a comprehensive and prospective series of sarcoma patients in the Rhone-Alpes region.
- Author
-
Lurkin A, Ducimetière F, Vince DR, Decouvelaere AV, Cellier D, Gilly FN, Salameire D, Biron P, de Laroche G, Blay JY, and Ray-Coquard I
- Subjects
- Adolescent, Adult, Aged, Aged, 80 and over, Case-Control Studies, Female, France epidemiology, Humans, Male, Middle Aged, Prospective Studies, Sarcoma diagnosis, Young Adult, Sarcoma epidemiology, Sarcoma pathology
- Abstract
Background: Sarcomas are rare malignant tumors. Accurate initial histological diagnosis is essential for adequate management. We prospectively assessed the medical management of all patients diagnosed with sarcoma in a European region over a one-year period to identify the quantity of first diagnosis compared to central expert review (CER)., Methods: Histological data of all patients diagnosed with sarcoma in Rhone-Alpes between March 2005 and Feb 2006 were collected. Primary diagnoses were systematically compared with second opinion from regional and national experts., Results: Of 448 patients included, 366 (82%) matched the inclusion criteria and were analyzed. Of these, 199 (54%) had full concordance between primary diagnosis and second opinion (the first pathologist and the expert reached identical conclusions), 97 (27%) had partial concordance (identical diagnosis of conjonctive tumor but different grade or subtype), and 70 (19%) had complete discordance (different histological type or invalidation of the diagnosis of sarcoma). The major discrepancies were related to histological grade (n = 68, 19%), histological type (n = 39, 11%), subtype (n = 17, 5%), and grade plus subtype or grade plus histological type (n = 43, 12%)., Conclusions: Over 45% of first histological diagnoses were modified at second reading, possibly resulting in different treatment decisions. Systematic second expert opinion improves the quality of diagnosis and possibly the management of patients.
- Published
- 2010
- Full Text
- View/download PDF
Catalog
Discovery Service for Jio Institute Digital Library
For full access to our library's resources, please sign in.